Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 1,900 shares, a drop of 17.4% from the August 31st total of 2,300 shares. Based on an average trading volume of 3,600 shares, the short-interest ratio is presently 0.5 days.

Santen Pharmaceutical Trading Up 0.2 %

SNPHY opened at $12.66 on Monday. The company has a 50 day simple moving average of $12.15 and a two-hundred day simple moving average of $10.78. Santen Pharmaceutical has a 1-year low of $8.31 and a 1-year high of $13.00.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.